Cyriac Abby Philips1, Nikhil Phadke2, Karthik Ganesan3, Shatakshi Ranade2, Philip Augustine4. 1. The Liver Unit, Cochin Gastroenterology Group, Ernakulam Medical Centre, National Highway Bypass (NH-66), Palarivattom, Kochi, 682 028, India. abbyphilips@gmail.com. 2. Molecular, Cellular and Developmental Biology, Genepath-Dx, 1260, Jangali Maharaj Road, Shivajinagar, Pune, 411 004, India. 3. Helical Bío, Ann Arbor, Michigan, United States of America. 4. Gastroenterology, Cochin Gastroenterology Group, Ernakulam Medical Centre, National Highway Bypass (NH-66), Palarivattom, Kochi, 682 028, India.
Abstract
INTRODUCTION: Alcohol-induced intestinal dysbiosis is central to the development of the severe alcoholic liver disease. We present the first study to compare outcomes in patients of severe alcoholic hepatitis (SAH) on nutritional therapy, corticosteroids, pentoxifylline, and healthy donor fecal transplantation (FMT) and discuss distinct microbial community and microbiome metabolic functional changes after FMT. METHODS: Out of 1271 liver disease patients, 809 (63.7%) were diagnosed to have the alcoholic liver disease, of which 51 patients (8 treated with corticosteroids, 17 with nutritional support only, 10 with pentoxifylline, 16 receiving FMT) were included. Clinical, biochemical parameters, liver disease, and alcoholic hepatitis severity scores at baseline and mortality at the end of 1 and 3 months were analyzed between groups. Stool microbiota (SM) analysis was performed for healthy controls (HC) and respective recipients after FMT. RESULTS: All the patients were male. The proportions of patients surviving at the end of 1 and 3 months in the steroids, nutrition, pentoxifylline, and FMT group were 63%, 47%, 40% and 75% [p = 0.179] and 38%, 29%, 30%, and 75% [p = 0.036], respectively. When compared with FMT, relative risk and hazard ratios for death were higher in all the other groups. Following FMT, distinct and beneficial modulation of SM and pathways of dysregulated metabolism, infections, inflammation, and oxidative stress in SAH patients were noted in tandem with improved clinical outcomes. CONCLUSIONS: Healthy donor FMT for SAH improves survival beyond what is offered by current therapies and can function as a cost-effective bridge to liver transplant (LT) or for improving transplant-free survival. Larger studies and randomized trials are unmet needs.
INTRODUCTION:Alcohol-induced intestinal dysbiosis is central to the development of the severe alcoholic liver disease. We present the first study to compare outcomes in patients of severe alcoholic hepatitis (SAH) on nutritional therapy, corticosteroids, pentoxifylline, and healthy donor fecal transplantation (FMT) and discuss distinct microbial community and microbiome metabolic functional changes after FMT. METHODS: Out of 1271 liver diseasepatients, 809 (63.7%) were diagnosed to have the alcoholic liver disease, of which 51 patients (8 treated with corticosteroids, 17 with nutritional support only, 10 with pentoxifylline, 16 receiving FMT) were included. Clinical, biochemical parameters, liver disease, and alcoholic hepatitis severity scores at baseline and mortality at the end of 1 and 3 months were analyzed between groups. Stool microbiota (SM) analysis was performed for healthy controls (HC) and respective recipients after FMT. RESULTS: All the patients were male. The proportions of patients surviving at the end of 1 and 3 months in the steroids, nutrition, pentoxifylline, and FMT group were 63%, 47%, 40% and 75% [p = 0.179] and 38%, 29%, 30%, and 75% [p = 0.036], respectively. When compared with FMT, relative risk and hazard ratios for death were higher in all the other groups. Following FMT, distinct and beneficial modulation of SM and pathways of dysregulated metabolism, infections, inflammation, and oxidative stress in SAHpatients were noted in tandem with improved clinical outcomes. CONCLUSIONS: Healthy donor FMT for SAH improves survival beyond what is offered by current therapies and can function as a cost-effective bridge to liver transplant (LT) or for improving transplant-free survival. Larger studies and randomized trials are unmet needs.
Authors: Lixin Zhu; Susan S Baker; Chelsea Gill; Wensheng Liu; Razan Alkhouri; Robert D Baker; Steven R Gill Journal: Hepatology Date: 2013-01-08 Impact factor: 17.425
Authors: Simone S Li; Ana Zhu; Vladimir Benes; Paul I Costea; Rajna Hercog; Falk Hildebrand; Jaime Huerta-Cepas; Max Nieuwdorp; Jarkko Salojärvi; Anita Y Voigt; Georg Zeller; Shinichi Sunagawa; Willem M de Vos; Peer Bork Journal: Science Date: 2016-04-29 Impact factor: 47.728
Authors: M Llopis; A M Cassard; L Wrzosek; L Boschat; A Bruneau; G Ferrere; V Puchois; J C Martin; P Lepage; T Le Roy; L Lefèvre; B Langelier; F Cailleux; A M González-Castro; S Rabot; F Gaudin; H Agostini; S Prévot; D Berrebi; D Ciocan; C Jousse; S Naveau; P Gérard; G Perlemuter Journal: Gut Date: 2015-12-07 Impact factor: 23.059
Authors: Jasmohan S Bajaj; Douglas M Heuman; Phillip B Hylemon; Arun J Sanyal; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel B Unser; Kalyani Daita; Andmorgan R Fisher; Masoumeh Sikaroodi; Patrick M Gillevet Journal: J Hepatol Date: 2013-12-25 Impact factor: 25.083
Authors: Mark R Thursz; Paul Richardson; Michael Allison; Andrew Austin; Megan Bowers; Christopher P Day; Nichola Downs; Dermot Gleeson; Alastair MacGilchrist; Allister Grant; Steven Hood; Steven Masson; Anne McCune; Jane Mellor; John O'Grady; David Patch; Ian Ratcliffe; Paul Roderick; Louise Stanton; Nikhil Vergis; Mark Wright; Stephen Ryder; Ewan H Forrest Journal: N Engl J Med Date: 2015-04-23 Impact factor: 91.245
Authors: Manuela G Neuman; Yaakov Maor; Radu M Nanau; Ehud Melzer; Haim Mell; Mihai Opris; Lawrence Cohen; Stephen Malnick Journal: Biomolecules Date: 2015-08-28